SPOTLIGHT: India emerging as big drug market

Indian pharma companies have had to weather a series of big changes in recent times, including big pharma's successful strategy in aggressively challenging generics. But the Wall Street Journal's trend piece also notes that over the next decade Indians' appetite for drugs will grow from $8 billion to $30 billion, making it an important market for the drug companies. Report

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.